Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

DNA Damage by an essential enzyme: A delicate balance act on the tightrope.

Nitiss KC, Nitiss JL, Hanakahi LA.

DNA Repair (Amst). 2019 Oct;82:102639. doi: 10.1016/j.dnarep.2019.102639. Epub 2019 Jul 9. Review.

PMID:
31437813
2.

A complex suite of loci and elements in eukaryotic type II topoisomerases determine selective sensitivity to distinct poisoning agents.

Blower TR, Bandak A, Lee ASY, Austin CA, Nitiss JL, Berger JM.

Nucleic Acids Res. 2019 Sep 5;47(15):8163-8179. doi: 10.1093/nar/gkz579.

3.

Detection of Topoisomerase Covalent Complexes in Eukaryotic Cells.

Anand J, Sun Y, Zhao Y, Nitiss KC, Nitiss JL.

Methods Mol Biol. 2018;1703:283-299. doi: 10.1007/978-1-4939-7459-7_20.

PMID:
29177749
4.

TDP1 is required for efficient non-homologous end joining in human cells.

Li J, Summerlin M, Nitiss KC, Nitiss JL, Hanakahi LA.

DNA Repair (Amst). 2017 Dec;60:40-49. doi: 10.1016/j.dnarep.2017.10.003. Epub 2017 Oct 16.

PMID:
29078113
5.

Effects of an unusual poison identify a lifespan role for Topoisomerase 2 in Saccharomyces cerevisiae.

Tombline G, Millen JI, Polevoda B, Rapaport M, Baxter B, Van Meter M, Gilbertson M, Madrey J, Piazza GA, Rasmussen L, Wennerberg K, White EL, Nitiss JL, Goldfarb DS.

Aging (Albany NY). 2017 Jan 5;9(1):68-97. doi: 10.18632/aging.101114.

6.

Roles of eukaryotic topoisomerases in transcription, replication and genomic stability.

Pommier Y, Sun Y, Huang SN, Nitiss JL.

Nat Rev Mol Cell Biol. 2016 Nov;17(11):703-721. doi: 10.1038/nrm.2016.111. Epub 2016 Sep 21. Review.

PMID:
27649880
7.

TDP1 promotes assembly of non-homologous end joining protein complexes on DNA.

Heo J, Li J, Summerlin M, Hays A, Katyal S, McKinnon PJ, Nitiss KC, Nitiss JL, Hanakahi LA.

DNA Repair (Amst). 2015 Jun;30:28-37. doi: 10.1016/j.dnarep.2015.03.003. Epub 2015 Mar 17.

8.

Twisting and ironing: doxorubicin cardiotoxicity by mitochondrial DNA damage.

Nitiss KC, Nitiss JL.

Clin Cancer Res. 2014 Sep 15;20(18):4737-9. doi: 10.1158/1078-0432.CCR-14-0821. Epub 2014 Jun 10.

9.

Proteolytic degradation of topoisomerase II (Top2) enables the processing of Top2·DNA and Top2·RNA covalent complexes by tyrosyl-DNA-phosphodiesterase 2 (TDP2).

Gao R, Schellenberg MJ, Huang SY, Abdelmalak M, Marchand C, Nitiss KC, Nitiss JL, Williams RS, Pommier Y.

J Biol Chem. 2014 Jun 27;289(26):17960-9. doi: 10.1074/jbc.M114.565374. Epub 2014 May 7.

10.

Aberrant topoisomerase-1 DNA lesions are pathogenic in neurodegenerative genome instability syndromes.

Katyal S, Lee Y, Nitiss KC, Downing SM, Li Y, Shimada M, Zhao J, Russell HR, Petrini JH, Nitiss JL, McKinnon PJ.

Nat Neurosci. 2014 Jun;17(6):813-21. doi: 10.1038/nn.3715. Epub 2014 May 4.

11.

Tdp2: a means to fixing the ends.

Nitiss JL, Nitiss KC.

PLoS Genet. 2013;9(3):e1003370. doi: 10.1371/journal.pgen.1003370. Epub 2013 Mar 7. No abstract available.

12.

The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II.

Hasinoff BB, Wu X, Nitiss JL, Kanagasabai R, Yalowich JC.

Biochem Pharmacol. 2012 Dec 15;84(12):1617-26. doi: 10.1016/j.bcp.2012.09.023. Epub 2012 Oct 5.

13.

Topoisomerase assays.

Nitiss JL, Soans E, Rogojina A, Seth A, Mishina M.

Curr Protoc Pharmacol. 2012 Jun;Chapter 3:Unit 3.3.. doi: 10.1002/0471141755.ph0303s57.

14.

Chemical reactivity and microbicidal action of bethoxazin.

Chee GL, Bhattarai B, Daniel Gietz R, Alrushaid S, Nitiss JL, Hasinoff BB.

Bioorg Med Chem. 2012 Feb 15;20(4):1494-501. doi: 10.1016/j.bmc.2011.12.051. Epub 2012 Jan 5.

PMID:
22264763
15.

End-processing during non-homologous end-joining: a role for exonuclease 1.

Bahmed K, Seth A, Nitiss KC, Nitiss JL.

Nucleic Acids Res. 2011 Feb;39(3):970-8. doi: 10.1093/nar/gkq886. Epub 2010 Oct 8.

16.

Yeast Tdp1 regulates the fidelity of nonhomologous end joining.

Bahmed K, Nitiss KC, Nitiss JL.

Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4057-62. doi: 10.1073/pnas.0909917107. Epub 2010 Feb 16.

17.

UnTTrapping the ends: a new player in overcoming protein linked DNA damage.

Bahmed K, Nitiss KC, Nitiss JL.

Cell Res. 2010 Feb;20(2):122-3. doi: 10.1038/cr.2010.17. No abstract available.

PMID:
20118967
18.

Targeting DNA topoisomerase II in cancer chemotherapy.

Nitiss JL.

Nat Rev Cancer. 2009 May;9(5):338-50. doi: 10.1038/nrc2607. Epub 2009 Apr 20. Review.

19.

DNA topoisomerase II and its growing repertoire of biological functions.

Nitiss JL.

Nat Rev Cancer. 2009 May;9(5):327-37. doi: 10.1038/nrc2608. Epub 2009 Apr 20. Review.

20.

Isolation and characterization of mAMSA-hypersensitive mutants. Cytotoxicity of Top2 covalent complexes containing DNA single strand breaks.

Rogojina AT, Nitiss JL.

J Biol Chem. 2008 Oct 24;283(43):29239-50. doi: 10.1074/jbc.M804058200. Epub 2008 Aug 22.

21.

Enhancing drug accumulation in Saccharomyces cerevisiae by repression of pleiotropic drug resistance genes with chimeric transcription repressors.

Stepanov A, Nitiss KC, Neale G, Nitiss JL.

Mol Pharmacol. 2008 Aug;74(2):423-31. doi: 10.1124/mol.107.044651. Epub 2008 May 9.

22.

Assessing sensitivity to antibacterial topoisomerase II inhibitors.

Morgan-Linnell SK, Hiasa H, Zechiedrich L, Nitiss JL.

Curr Protoc Pharmacol. 2007 Dec;Chapter 3:Unit3.13. doi: 10.1002/0471141755.ph0313s39.

23.

Mutation of a conserved active site residue converts tyrosyl-DNA phosphodiesterase I into a DNA topoisomerase I-dependent poison.

He X, van Waardenburg RCAM, Babaoglu K, Price AC, Nitiss KC, Nitiss JL, Bjornsti MA, White SW.

J Mol Biol. 2007 Sep 28;372(4):1070-1081. doi: 10.1016/j.jmb.2007.07.055. Epub 2007 Aug 2.

PMID:
17707402
24.

Repair of topoisomerase I-mediated DNA damage.

Pommier Y, Barcelo JM, Rao VA, Sordet O, Jobson AG, Thibaut L, Miao ZH, Seiler JA, Zhang H, Marchand C, Agama K, Nitiss JL, Redon C.

Prog Nucleic Acid Res Mol Biol. 2006;81:179-229. Review. No abstract available.

25.

Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.

Malik M, Nitiss KC, Enriquez-Rios V, Nitiss JL.

Mol Cancer Ther. 2006 Jun;5(6):1405-14.

26.

Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage.

Nitiss KC, Malik M, He X, White SW, Nitiss JL.

Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):8953-8. Epub 2006 Jun 2.

27.
28.

Gimatecan (sigma-tau industrie farmaceutiche riunite/novartis).

Nitiss JL, Nitiss KC.

IDrugs. 2005 Jul;8(7):578-88. Review.

PMID:
15973567
29.

Stability of the topoisomerase II closed clamp conformation may influence DNA-stimulated ATP hydrolysis.

Vaughn J, Huang S, Wessel I, Sorensen TK, Hsieh T, Jensen LH, Jensen PB, Sehested M, Nitiss JL.

J Biol Chem. 2005 Mar 25;280(12):11920-9. Epub 2005 Jan 12.

30.

Biochemical and proteomics approaches to characterize topoisomerase IIalpha cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIalpha.

Hasinoff BB, Wu X, Krokhin OV, Ens W, Standing KG, Nitiss JL, Sivaram T, Giorgianni A, Yang S, Jiang Y, Yalowich JC.

Mol Pharmacol. 2005 Mar;67(3):937-47. Epub 2004 Dec 15.

PMID:
15602006
31.

A mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase II.

Gruger T, Nitiss JL, Maxwell A, Zechiedrich EL, Heisig P, Seeber S, Pommier Y, Strumberg D.

Antimicrob Agents Chemother. 2004 Dec;48(12):4495-504.

32.

A mutation in human topoisomerase II alpha whose expression is lethal in DNA repair-deficient yeast cells.

Walker JV, Nitiss KC, Jensen LH, Mayne C, Hu T, Jensen PB, Sehested M, Hsieh T, Nitiss JL.

J Biol Chem. 2004 Jun 18;279(25):25947-54. Epub 2004 Mar 22.

33.
34.

Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance.

Renodon-Cornière A, Jensen LH, Nitiss JL, Jensen PB, Sehested M.

Biochemistry. 2003 Aug 19;42(32):9749-54.

PMID:
12911317
35.

A dual mechanism of action of the anticancer agent F 11782 on human topoisomerase II alpha.

Jensen LH, Renodon-Cornière A, Nitiss KC, Hill BT, Nitiss JL, Jensen PB, Sehested M.

Biochem Pharmacol. 2003 Aug 15;66(4):623-31.

PMID:
12906927
36.

Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks.

Sabourin M, Nitiss JL, Nitiss KC, Tatebayashi K, Ikeda H, Osheroff N.

Nucleic Acids Res. 2003 Aug 1;31(15):4373-84.

37.

Probing the role of linker substituents in bisdioxopiperazine analogs for activity against wild-type and mutant human topoisomerase II alpha.

Renodon-Cornière A, Sørensen TK, Jensen PB, Nitiss JL, Søkilde B, Sehested M, Jensen LH.

Mol Pharmacol. 2003 May;63(5):1159-68.

PMID:
12695544
38.

DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage.

Nitiss JL.

Curr Opin Investig Drugs. 2002 Oct;3(10):1512-6. Review.

PMID:
12431029
39.

Interaction of human DNA topoisomerase II alpha with DNA: quantification by surface plasmon resonance.

Renodon-Cornière A, Jensen LH, Nitiss JL, Jensen PB, Sehested M.

Biochemistry. 2002 Nov 12;41(45):13395-402.

PMID:
12416984
40.

A copper connection to the uptake of platinum anticancer drugs.

Nitiss JL.

Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):13963-5. Epub 2002 Oct 21. Review. No abstract available.

41.

Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.

Rothenborg-Jensen L, Hansen HF, Wessel I, Nitiss JL, Schmidt G, Jensen PB, Sehested M, Jensen LH.

Anticancer Drug Des. 2001 Dec;16(6):305-15.

PMID:
12375883
42.

Importance of the fourth alpha-helix within the CAP homology domain of type II topoisomerase for DNA cleavage site recognition and quinolone action.

Strumberg D, Nitiss JL, Dong J, Walker J, Nicklaus MC, Kohn KW, Heddle JG, Maxwell A, Seeber S, Pommier Y.

Antimicrob Agents Chemother. 2002 Sep;46(9):2735-46.

43.

DNA topoisomerase II as a target for cancer chemotherapy.

Walker JV, Nitiss JL.

Cancer Invest. 2002;20(4):570-89. Review. No abstract available.

PMID:
12094551
44.
45.

Antifungal activity of eupolauridine and its action on DNA topoisomerases.

Khan SI, Nimrod AC, Mehrpooya M, Nitiss JL, Walker LA, Clark AM.

Antimicrob Agents Chemother. 2002 Jun;46(6):1785-92.

46.

Overexpression of type I topoisomerases sensitizes yeast cells to DNA damage.

Nitiss JL, Nitiss KC, Rose A, Waltman JL.

J Biol Chem. 2001 Jul 13;276(28):26708-14. Epub 2001 May 15.

47.

Topoisomerase assays.

Nitiss JL.

Curr Protoc Pharmacol. 2001 May;Chapter 3:Unit3.3. doi: 10.1002/0471141755.ph0303s00. No abstract available.

PMID:
21971799
48.

Topoisomerase I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine.

Pourquier P, Waltman JL, Urasaki Y, Loktionova NA, Pegg AE, Nitiss JL, Pommier Y.

Cancer Res. 2001 Jan 1;61(1):53-8.

49.

Yeast systems for demonstrating the targets of anti-topoisomerase II agents.

Nitiss JL, Nitiss KC.

Methods Mol Biol. 2001;95:315-27. No abstract available.

PMID:
11089243
50.

Thioguanine substitution alters DNA cleavage mediated by topoisomerase II.

Krynetskaia NF, Cai X, Nitiss JL, Krynetski EY, Relling MV.

FASEB J. 2000 Nov;14(14):2339-44.

PMID:
11053256

Supplemental Content

Loading ...
Support Center